Renchuang Future

Renchuang Future is an innovative Chinese biotechnology company specializing in the development of next-generation gene therapies through proprietary base-editing technologies. Founded by experts from institutions like ShanghaiTech University, the company focuses on high-efficiency Glycosylase-mediated Base Editors (GBEs) that enable precise C-to-G or A-to-G conversions without inducing double-strand DNA breaks. Their lead research programs target hematological disorders, specifically beta-thalassemia, aiming to provide curative outcomes with improved safety profiles compared to traditional CRISPR/Cas9 methods. Based in the Suzhou BioBAY industrial park, Renchuang Future is actively advancing its pipeline toward IND-enabling studies and clinical trials.